Influx of capital will fuel WiL Ventures III fund, WiL Strategic Partners funds and Corporate Venture Capital funds; WiL’s capital commitments now exceed $1.9 billion WiL’s mission: bridge the innovation gap between Japan, the US and the rest of the world WiL’s investment thesis: provide growth investment capital for innovators across the spectrum of digital … [Read more…]
– No cerebral vascular anomaly before and after treatment observed – Successful completion of the FIM II clinical study prior to the pivotal study, that will pave the way for CE marking PARIS–(BUSINESS WIRE)–Cardiawave SA, a deeptech medical device manufacturer that has developed VALVOSOFT® a revolutionary non-invasive medical device to treat aortic stenosis, the most … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “General Anxiety Disorder Therapeutics Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type” report has been added to ResearchAndMarkets.com’s offering. This report describes the global market size of General Anxiety Disorder Therapeutics from 2017 to 2021 and its CAGR from 2017 to 2021, and also forecasts … [Read more…]
MILAN–(BUSINESS WIRE)–#IVASC–I-VASC, the Italy based start-up company which has developed and CE Marked its innovative percutaneous VELEX™ system to treat CVI, a condition that includes varicose veins disease, announces today that VELEX™ has entered clinical use, with the first two cases performed last week in Milan at the Policlinico San Donato center, the renowned institution … [Read more…]
SEOUL, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced that its partner, I-Mab (Nasdaq: IMAB), recently completed patient enrollment in a phase 3 clinical trial of its proprietary long-acting growth hormone, eftansomatropin alfa, … [Read more…]
Investment co-led by Jonathan Milner and Cambridge Enterprise US-based R42 Group, ACF Investors, o2h Ventures, Syndicate Room and the Cambridge Angels investing Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours CAMBRIDGE, England–(BUSINESS WIRE)–Spirea Limited, a Cambridge company created to advance a new generation of … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Voice of the Industry: Consumer Health” report has been added to ResearchAndMarkets.com’s offering. In the Voice of the Industry Survey series, the analyst connects with industry professionals to explore trends and innovations. This report focuses on the consumer health industry, drawing on the Voice of the Industry: Consumer Health Survey. The global briefing … [Read more…]
LONDON–(BUSINESS WIRE)–AIBODY, the world’s first Physiology-as-a-Service platform, announced today that it will partner with Relias, the United States-based healthcare education and workforce development leader, to develop an innovative range of digital study materials for professional medical training. Specializing in healthcare education solutions, Relias helps more than 11,000 organizations and 4.5 million caregivers elevate care to … [Read more…]
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–$RDY #BayerHealthCare–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Dr. Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar® (sorafenib) Tablets in the U.S. market following the approval … [Read more…]
LYT-300 achieved systemic blood levels approximately nine-fold greater compared to previous reports with oral allopregnanolone.1 Allopregnanolone is a neurosteroid with proven efficacy that is currently only approved as a 60-hour intravenous infusion. LYT-300, an orally administered prodrug of allopregnanolone, is designed to be differentiated from synthetic analogs, which may not replicate the full target engagement … [Read more…]
